Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis

References

• Patel MM, Hall AJ, Vinjé J, Parashar UD. Noroviruses: a comprehensive review. J. Clin. Virol. 44(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Hall AJ, Rosenthal M, Gregoricus N et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004–2005. Emerging Infect. Dis. 17(8), 1381–1388 (2011).
   PubMed Web of Science ®Google Scholar
• Hall AJ. Noroviruses: the perfect human pathogens? J. Infect. Dis. 205(11), 1622–1624 (2012).
   PubMed Web of Science ®Google Scholar
• Karst SM. Pathogenesis of noroviruses, emerging RNA viruses. Viruses 2(3), 748–781 (2010).
   PubMed Web of Science ®Google Scholar
• Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9(3), 299–307 (2010).
   PubMed Web of Science ®Google Scholar
• Atmar RL. Noroviruses – state of the art. Food Environ. Virol. 2(3), 117–126 (2010).
   PubMedGoogle Scholar
• Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8(3), 231–241 (2010).
   PubMed Web of Science ®Google Scholar
• Bresee JS, Widdowson MA, Monroe SS, Glass RI. Foodborne viral gastroenteritis: challenges and opportunities. Clin. Infect. Dis. 35(6), 748–753 (2002).
   PubMedGoogle Scholar
• Scallan E, Hoekstra RM, Angulo FJ et al. Foodborne illness acquired in the United States – major pathogens. Emerging Infect. Dis. 17(1), 7–15 (2011).
   PubMed Web of Science ®Google Scholar
• Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996–2007. Clin. Infect. Dis. 52(4), 466–474 (2011).
   PubMed Web of Science ®Google Scholar
• Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin. Infect. Dis. 55(2), 216–223 (2012).
   PubMed Web of Science ®Google Scholar
• Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine 30(49), 7097–7104 (2012).
   PubMed Web of Science ®Google Scholar
• Zahorsky J. Hyperemesis hiemis or the winter vomiting disease. Arch. Pediatr. 46, 391–395 (1929).
   Google Scholar
• Kapikian AZ. The discovery of the 27-nm Norwalk virus: an historic perspective. J. Infect. Dis. 181(Suppl. 2), S295–S302 (2000).
   PubMedGoogle Scholar
• Xi JN, Graham DY, Wang KN, Estes MK. Norwalk virus genome cloning and characterization. Science 250(4987), 1580–1583 (1990).
   PubMed Web of Science ®Google Scholar
• Widdowson MA, Monroe SS, Glass RI. Are noroviruses emerging? Emerging Infect. Dis. 11(5), 735–737 (2005).
   PubMedGoogle Scholar
• van Asten L, van den Wijngaard C, van Pelt W et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J. Infect. Dis. 206(5), 628–639 (2012).
   PubMed Web of Science ®Google Scholar
• van Asten L, Siebenga J, van den Wijngaard C et al. Unspecified gastroenteritis illness and deaths in the elderly associated with norovirus epidemics. Epidemiology 22(3), 336–343 (2011).
   PubMedGoogle Scholar
• Rondy M, Koopmans M, Rotsaert C et al. Norovirus disease associated with excess mortality and use of statins: a retrospective cohort study of an outbreak following a pilgrimage to Lourdes. Epidemiol. Infect. 139(3), 453–463 (2011).
   PubMedGoogle Scholar
• Desai R, Hembree CD, Handel A et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin. Infect. Dis. 55(2), 189–193 (2012).
   PubMed Web of Science ®Google Scholar
• Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinjé J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerging Infect. Dis. 14(8), 1224–1231 (2008).
   PubMed Web of Science ®Google Scholar
• Teunis PF, Moe CL, Liu P et al. Norwalk virus: how infectious is it? J. Med. Virol. 80(8), 1468–1476 (2008).
   PubMed Web of Science ®Google Scholar
• Atmar RL, Opekun AR, Gilger MA et al. Norwalk virus shedding after experimental human infection. Emerging Infect. Dis. 14(10), 1553–1557 (2008).
   PubMed Web of Science ®Google Scholar
• Aoki Y, Suto A, Mizuta K, Ahiko T, Osaka K, Matsuzaki Y. Duration of norovirus excretion and the longitudinal course of viral load in norovirus-infected elderly patients. J. Hosp. Infect. 75(1), 42–46 (2010).
   PubMedGoogle Scholar
• Siebenga JJ, Beersma MF, Vennema H, van Biezen P, Hartwig NJ, Koopmans M. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution. J. Infect. Dis. 198(7), 994–1001 (2008).
   PubMed Web of Science ®Google Scholar
• Lopman B, Gastañaduy P, Park GW, Hall AJ, Parashar UD, Vinjé J. Environmental transmission of norovirus gastroenteritis. Curr. Opin. Virol. 2(1), 96–102 (2012).
   PubMed Web of Science ®Google Scholar
• Green KY. Caliciviridae: the noroviruses. In: Fields Virology. Knipe HP, Howley PM (Eds). Lippincott, Williams & Wilkins Publishers, PA, USA, 949–979 (2007).
   Google Scholar
• Glass PJ, White LJ, Ball JM, Leparc-Goffart I, Hardy ME, Estes MK. Norwalk virus open reading frame 3 encodes a minor structural protein. J. Virol. 74(14), 6581–6591 (2000).
   PubMed Web of Science ®Google Scholar
• Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 286(5438), 287–290 (1999).
   PubMed Web of Science ®Google Scholar
• Zakikhany K, Allen DJ, Brown D, Iturriza-Gómara M. Molecular evolution of GII-4 norovirus strains. PLoS ONE 7(7), e41625 (2012).
   PubMedGoogle Scholar
• Chakravarty S, Hutson AM, Estes MK, Prasad BV. Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J. Virol. 79(1), 554–568 (2005).
   PubMedGoogle Scholar
• Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66(11), 6527–6532 (1992).
   PubMed Web of Science ®Google Scholar
• Tan M, Hegde RS, Jiang X. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J. Virol. 78(12), 6233–6242 (2004).
   PubMedGoogle Scholar
• Tan M, Jiang X. The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J. Virol. 79(22), 14017–14030 (2005).
   PubMed Web of Science ®Google Scholar
• Tan M, Jiang X. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond.) 7(6), 889–897 (2012).
   PubMed Web of Science ®Google Scholar
• Straub TM, Höner zu Bentrup K, Orosz-Coghlan P et al. in vitro cell culture infectivity assay for human noroviruses. Emerging Infect. Dis. 13(3), 396–403 (2007).
   PubMed Web of Science ®Google Scholar
• Herbst-Kravoletz M, Hjeelm B, Lay M et al. Lack of success in culturing Noroviruses in 3-D culture systems. Presented at: 5th International Conference on Vaccines for Enteric Diseases. Malaga, Spain, 9–11 September 2009.
   Google Scholar
• Papfragkou E, Hewitt J, Park GW, Straub TM, Geening G, Vinje J. Challenges of culturing human norovirus in 3-D organoid cell model. Presented at: 109th General Meeting of the American Society for Microbiology. Philadelphia, PA, USA, 17–21 May 2009.
   Google Scholar
• Wobus CE, Karst SM, Thackray LB et al. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2(12), e432 (2004).
   PubMed Web of Science ®Google Scholar
• Lay MK, Atmar RL, Guix S et al. Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology 406(1), 1–11 (2010).
   PubMedGoogle Scholar
• Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85(Pt 1), 79–87 (2004).
   PubMed Web of Science ®Google Scholar
• Rockx BH, Bogers WM, Heeney JL, van Amerongen G, Koopmans MP. Experimental norovirus infections in non-human primates. J. Med. Virol. 75(2), 313–320 (2005).
   PubMed Web of Science ®Google Scholar
• Subekti DS, Tjaniadi P, Lesmana M et al. Experimental infection of Macaca nemestrina with a Toronto Norwalk-like virus of epidemic viral gastroenteritis. J. Med. Virol. 66(3), 400–406 (2002).
   PubMedGoogle Scholar
• Bok K, Parra GI, Mitra T et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl Acad. Sci. USA 108(1), 325–330 (2011).
   PubMed Web of Science ®Google Scholar
• Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J. Virol. 80(21), 10372–10381 (2006).
   PubMed Web of Science ®Google Scholar
• Cheetham S, Souza M, McGregor R, Meulia T, Wang Q, Saif LJ. Binding patterns of human norovirus-like particles to buccal and intestinal tissues of gnotobiotic pigs in relation to A/H histo-blood group antigen expression. J. Virol. 81(7), 3535–3544 (2007).
   PubMedGoogle Scholar
• Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 346(2), 312–323 (2006).
   PubMed Web of Science ®Google Scholar
• Dolin R, Blacklow NR, DuPont H et al. Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteritis. Proc. Soc. Exp. Biol. Med. 140(2), 578–583 (1972).
   PubMed Web of Science ®Google Scholar
• Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297(2), 86–89 (1977).
   PubMed Web of Science ®Google Scholar
• Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J. Infect. Dis. 161(1), 18–21 (1990).
   PubMed Web of Science ®Google Scholar
• Wyatt RG, Dolin R, Blacklow NR et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J. Infect. Dis. 129(6), 709–714 (1974).
   PubMed Web of Science ®Google Scholar
• Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 185(9), 1335–1337 (2002).
   PubMed Web of Science ®Google Scholar
• Lindesmith L, Moe C, Marionneau S et al. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9(5), 548–553 (2003).
   PubMed Web of Science ®Google Scholar
• Marionneau S, Ruvoën N, Le Moullac-Vaidye B et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122(7), 1967–1977 (2002).
   PubMed Web of Science ®Google Scholar
• Thorven M, Grahn A, Hedlund KO et al. A homozygous nonsense mutation (428G–>A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J. Virol. 79(24), 15351–15355 (2005).
   PubMed Web of Science ®Google Scholar
• Reeck A, Kavanagh O, Estes MK et al. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202(8), 1212–1218 (2010).
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Harro CD et al. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365(23), 2178–2187 (2011).
   PubMed Web of Science ®Google Scholar
• Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J. Virol. 79(5), 2900–2909 (2005).
   PubMed Web of Science ®Google Scholar
• Shirato H, Ogawa S, Ito H et al. Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J. Virol. 82(21), 10756–10767 (2008).
   PubMedGoogle Scholar
• Nordgren J, Kindberg E, Lindgren PE, Matussek A, Svensson L. Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerging Infect. Dis. 16(1), 81–87 (2010).
   PubMedGoogle Scholar
• Takanashi S, Wang Q, Chen N et al. Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J. Clin. Microbiol. 49(9), 3234–3244 (2011).
   PubMedGoogle Scholar
• Tan M, Jiang X. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol. 19(8), 382–388 (2011).
   PubMed Web of Science ®Google Scholar
• Huang P, Farkas T, Zhong W et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol. 79(11), 6714–6722 (2005).
   PubMed Web of Science ®Google Scholar
• Tan M, Xia M, Chen Y et al. Conservation of carbohydrate binding interfaces-evidence of human HBGA selection in norovirus evolution. PLoS One 4(4) e5058 (2009).
   PubMed Web of Science ®Google Scholar
• Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N. Engl. J. Med. 361(18), 1776–1785 (2009).
   PubMed Web of Science ®Google Scholar
• Siebenga JJ, Vennema H, Renckens B et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81(18), 9932–9941 (2007).
   PubMed Web of Science ®Google Scholar
• Lindesmith LC, Donaldson EF, Lobue AD et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5(2), e31 (2008).
   PubMedGoogle Scholar
• Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS, Vinjé J. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J. Virol. 83(11), 5363–5374 (2009).
   PubMed Web of Science ®Google Scholar
• Yang Y, Xia M, Tan M et al. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J. Virol. 84(18), 9595–9607 (2010).
   PubMedGoogle Scholar
• Lindesmith LC, Beltramello M, Donaldson EF et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 8(5), e1002705 (2012).
   PubMed Web of Science ®Google Scholar
• Otto PH, Clarke IN, Lambden PR, Salim O, Reetz J, Liebler-Tenorio EM. Infection of calves with bovine norovirus GIII.1 strain Jena virus: an experimental model to study the pathogenesis of norovirus infection. J. Virol. 85(22), 12013–12021 (2011).
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol. Chem. 389(5), 521–536 (2008).
   PubMed Web of Science ®Google Scholar
• Xia M, Farkas T, Jiang X. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J. Med. Virol. 79(1), 74–83 (2007).
   PubMedGoogle Scholar
• Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl Acad. Sci. USA 93(11), 5335–5340 (1996).
   PubMed Web of Science ®Google Scholar
• Santi L, Batchelor L, Huang Z et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26(15), 1846–1854 (2008).
   PubMed Web of Science ®Google Scholar
• Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J. Biol. Chem. 281(28), 19478–19488 (2006).
   PubMed Web of Science ®Google Scholar
• Huhti L, Blazevic V, Nurminen K, Koho T, Hytönen VP, Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch. Virol. 155(11), 1855–1858 (2010).
   PubMed Web of Science ®Google Scholar
• Kissmann J, Ausar SF, Foubert TR et al. Physical stabilization of Norwalk virus-like particles. J. Pharm. Sci. 97(10), 4208–4218 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor RM. Production and downstream processing of norovirus virus-like particles. Presented at: 12th International Meeting, Baculovirus and Insect Cell Culture. San Antonio, TX, USA, 2–4 February 2009.
   Google Scholar
• Koho T, Mäntylä T, Laurinmäki P et al. Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J. Virol. Methods 181(1), 6–11 (2012).
   PubMedGoogle Scholar
• Lai H, Chen Q. Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell Rep. 31(3), 573–584 (2012).
   PubMed Web of Science ®Google Scholar
• Taylor RM. Production of Norovirus virus-like particles in the baculovirus expression system from benchtop to GMP manufacturing. Presented at: ISBioTech. Rosslyn, VA, USA, 2–4 April 2012.
   Google Scholar
• Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72(2), 1345–1353 (1998).
   PubMed Web of Science ®Google Scholar
• Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75(20), 9713–9722 (2001).
   PubMedGoogle Scholar
• Periwal SB, Kourie KR, Ramachandaran N et al. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine 21(5-6), 376–385 (2003).
   PubMed Web of Science ®Google Scholar
• Nicollier-Jamot B, Ogier A, Piroth L, Pothier P, Kohli E. Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specific humoral and cellular Th1/Th2-like immune responses. Vaccine 22(9-10), 1079–1086 (2004).
   PubMedGoogle Scholar
• Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 25(50), 8448–8459 (2007).
   PubMed Web of Science ®Google Scholar
• Steadman B, Hinchcliffe M, Tino WT, Wimer SK, Sublett R, Richardson C. Product development and clinical plan for a mucosally-delivered Norwalk vaccine. Presented at: VED 2007 Vaccines for Enteric Diseases. Lisbon, Portugal, 25–27 April 2007.
   Google Scholar
• Parra GI, Bok K, Taylor R et al. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30(24), 3580–3586 (2012).
   PubMed Web of Science ®Google Scholar
• LoBue AD, Lindesmith L, Yount B et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24(24), 5220–5234 (2006).
   PubMed Web of Science ®Google Scholar
• LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83(7), 3212–3227 (2009).
   PubMed Web of Science ®Google Scholar
• Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 117(1), 40–48 (1999).
   PubMed Web of Science ®Google Scholar
• Gray JJ, Cunliffe C, Ball J, Graham DY, Desselberger U, Estes MK. Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus. J. Clin. Microbiol. 32(12), 3059–3063 (1994).
   PubMedGoogle Scholar
• Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108(3), 241–247 (2003).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182(1), 302–305 (2000).
   PubMed Web of Science ®Google Scholar
• El-Kamary SS, Pasetti MF, Mendelman PM et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11), 1649–1658 (2010).
   PubMed Web of Science ®Google Scholar
• Ramirez K, Wahid R, Richardson C et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin. Immunol. 144(2), 98–108 (2012).
   PubMed Web of Science ®Google Scholar
• Frey SE, Treanor JJ, Atmar RL et al. Dose escalation trial of the safety and immunogenicity of a bivalent Norovirus virus-like particle vaccine administered by the intramuscular route. Presented at: 49th Annual Meeting of the Infectious Disease Society of America (IDSA). Boston, MA, USA, 20–23 October 2011.
   Google Scholar
• Treanor JJ, Frey S, Gormley R et al. Safety and immunogenicity of an intramuscular Norovirus VLP vaccine. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 9–12 September 2012.
   Google Scholar